By Karen Roman
Biopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial.
The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated.
“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm,” said Kristen K. Buck, Lisata’s EVP of Research and Development and Chief Medical Officer.
Contact:
